ChromoCure, Inc. Launches Pathologist Collaborative Research Program in Support of Project Boveri: Find the Cure Initiative

RENO, NV--(Marketwire - March 16, 2010) -

ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure announced today the launch of its Pathologist Collaborative Research Program in support of its groundbreaking Project Boveri: Find the Cure Initiative. Agreements are in place whereby selected pathologists provide cell samples of historical or current patients to the Company for analysis by its chromosomal scanning technology. Full results of the scan and analysis will be provided to the pathologist. Patient information or history is neither required nor supplied for the purpose of this research. The scan results will be compared to the diagnosis of the pathologist. The Company will continuously build its database of results as part of its larger clinical pre-trial efforts.

The research collaboration pathologists will be announced in conjunction with new research agreements.

The Company’s proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently employed by pathologists, including biomarker detection, in every measurable way.

Research has conclusively and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure’s systems measure aneuploidy as the sole means of detecting cancer presence and measuring cancer progression. The system has a 100% effective accuracy rate. The Company recently published its collaborative clinical testing with a major cancer clinic.

The Company’s focus on cancer research is further underscored by recent major clinical publications that both validate ChromoCure’s chromosomal/aneuploidy theory of cancer and establish the company’s detection approach as the forefront of both cancer detection and research.

The company’s technology and related research opens the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure’s scanner technologies include proprietary designs, processes, and algorithms centered on chromosomal imbalance. They provide the foundation for significant advantages in delivering important results in diagnosis, therapy and cure.

The Company invites industry and scientific collaboration through its “Project Boveri: Find the Cure” initiative.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company’s proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.